Organon & Co. (NYSE:OGN) Stock Holdings Increased by Deprince Race & Zollo Inc.

Deprince Race & Zollo Inc. increased its position in Organon & Co. (NYSE:OGN - Free Report) by 7.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 4,729,258 shares of the company's stock after purchasing an additional 308,267 shares during the period. Organon & Co. comprises about 1.4% of Deprince Race & Zollo Inc.'s investment portfolio, making the stock its 7th biggest holding. Deprince Race & Zollo Inc. owned 1.84% of Organon & Co. worth $70,561,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in OGN. Crestline Management LP bought a new position in shares of Organon & Co. during the 4th quarter worth approximately $463,000. Caption Management LLC acquired a new position in shares of Organon & Co. during the 4th quarter worth about $689,000. Cetera Investment Advisers raised its stake in Organon & Co. by 62.7% during the 4th quarter. Cetera Investment Advisers now owns 76,005 shares of the company's stock worth $1,134,000 after buying an additional 29,287 shares during the period. Brevan Howard Capital Management LP bought a new stake in shares of Organon & Co. in the fourth quarter worth $2,017,000. Finally, Captrust Financial Advisors grew its stake in Organon & Co. by 22.5% in the fourth quarter. Captrust Financial Advisors now owns 29,853 shares of the company's stock valued at $445,000 after purchasing an additional 5,489 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Insider Buying and Selling at Organon & Co.

In other news, VP Daniel Karp purchased 3,500 shares of the business's stock in a transaction on Tuesday, May 6th. The shares were acquired at an average cost of $8.24 per share, with a total value of $28,840.00. Following the completion of the acquisition, the vice president now owns 46,669 shares of the company's stock, valued at $384,552.56. This trade represents a 8.11% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kirke Weaver purchased 8,045 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were purchased at an average price of $9.21 per share, for a total transaction of $74,094.45. Following the purchase, the insider now owns 52,489 shares in the company, valued at approximately $483,423.69. The trade was a 18.10% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 102,345 shares of company stock valued at $902,430 in the last three months. 1.96% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on OGN shares. Barclays lowered their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Morgan Stanley dropped their target price on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Finally, Evercore ISI lowered shares of Organon & Co. from an "outperform" rating to an "inline" rating in a report on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $18.00.

Organon & Co. Trading Down 2.9%

OGN stock traded down $0.25 during trading on Tuesday, hitting $8.46. 3,310,545 shares of the company traded hands, compared to its average volume of 3,084,557. The firm has a market capitalization of $2.20 billion, a PE ratio of 2.54, a P/E/G ratio of 0.90 and a beta of 0.75. Organon & Co. has a 1 year low of $8.05 and a 1 year high of $23.10. The company has a 50-day moving average of $12.76 and a 200-day moving average of $14.56. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.13. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same quarter last year, the firm posted $1.22 earnings per share. The firm's revenue was down 6.7% on a year-over-year basis. Analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Monday, May 12th will be given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend is Monday, May 12th. Organon & Co.'s dividend payout ratio is currently 2.78%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.